<DOC>
	<DOC>NCT00730665</DOC>
	<brief_summary>To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (standard proton pump inhibitor [PPI] treatment), in subjects with gastro-esophageal reflux (GERD) who have inadequate relief with PPIs.</brief_summary>
	<brief_title>Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Subjects with a diagnosis of GERD who fulfill the following criteria: who have symptoms for least six months prior to enrollment; who are currently on daily treatment with a PPI and have been on such treatment for at least 3 months; whose symptoms are persistent, troublesome and that include heartburn and/or regurgitation as their predominant symptoms despite treatment with a PPI; who are seeking relief of persistent symptoms. Subjects with erosive esophagitis An endoscopy within the last 5 years is required to verify absence. Subjects with any esophageal or gastric diseases/conditions that may contribute to their GERD symptoms. If female; pregnant, lactating or positive serum or urine pregnancy tests.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>PPI partial responders with non-erosive GERD.</keyword>
</DOC>